Garry Menzel

Garry Menzel

Director/Board Member bei ADAPTIMMUNE THERAPEUTICS PLC

Vermögen: 537 011 $ am 31.03.2024

59 Jahre
Health Technology
Consumer Services
Finance

Profil

Garry E.
Menzel
is currently the Director at Epilepsy Therapy Project.
He also holds current positions as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, an Independent Director at Stoke Therapeutics, Inc., an Independent Director at Black Diamond Therapeutics, Inc., a Member-National Board at Epilepsy Foundation, the Principal at Royal College of Art, and an Operating Partner at GHO Capital Partners LLP.
In his former roles, Dr. Menzel served as the President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc. from 2016 to 2023.
He was also a Managing Director at Credit Suisse Group AG from 2004 to 2008 and at The Goldman Sachs Group, Inc. from 1994 to 2004.
Additionally, he held positions as the Chief Financial Officer at DaVita, Inc. from 2013 to 2015, the Chief Operating Officer at Regulus Therapeutics, Inc. from 2008 to 2013, and the Chief Strategy Officer at Axcella Health, Inc. from 2015 to 2016.
He has also worked as a Research Assistant at Smithkline Beecham Plc and as a Consultant at Bain & Co., Inc.Dr. Menzel's education includes an undergraduate degree from Imperial College London in 1985, a doctorate from the University of Cambridge, and an MBA from Stanford Graduate School of Business in 1994.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
16.05.2023 76 644 ( 0,15% ) 388 585 $ 31.03.2024
10.07.2023 563 522 ( 0,10% ) 148 426 $ 31.03.2024
01.09.2023 0 ( -.--% ) - $ 31.03.2024

Aktive Positionen von Garry Menzel

UnternehmenPositionBeginn
BLACK DIAMOND THERAPEUTICS, INC. Director/Board Member 01.01.2014
STOKE THERAPEUTICS, INC. Director/Board Member 13.08.2020
ADAPTIMMUNE THERAPEUTICS PLC Director/Board Member 01.06.2023
Corporate Officer/Principal 01.01.2003
Epilepsy Therapy Project Director/Board Member -
Royal College of Art Corporate Officer/Principal 17.03.2010
Private Equity Investor 23.04.2024
Alle aktiven Positionen von Garry Menzel

Ehemalige bekannte Positionen von Garry Menzel

UnternehmenPositionEnde
TCR2 THERAPEUTICS INC. Chief Executive Officer 01.01.2023
AXCA HEALPAR Corporate Officer/Principal 01.09.2016
░░░░░░ ░░░░ ░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░ ░░░░░ ░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Garry Menzel im Detail an

Ausbildung von Garry Menzel

Imperial College London Undergraduate Degree
University of Cambridge Doctorate Degree
Stanford Graduate School of Business Masters Business Admin

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Garry Menzel im Detail an

Beziehungen

100 +

Beziehungen ersten Grades

19

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen7
DAVITA INC.

Health Services

THE GOLDMAN SACHS GROUP, INC.

Finance

REGULUS THERAPEUTICS INC.

Health Technology

AXCA HEALPAR

Health Technology

STOKE THERAPEUTICS, INC.

Health Technology

BLACK DIAMOND THERAPEUTICS, INC.

Health Technology

ADAPTIMMUNE THERAPEUTICS PLC

Health Technology

Private Unternehmen8

Health Technology

Finance

Commercial Services

Commercial Services

Commercial Services

Epilepsy Therapy Project

Health Technology

Finance

Sehen Sie sich die Unternehmensverbindungen an
  1. Börse
  2. Insiders
  3. Garry Menzel